Brief: Regenerx Joint Venture Expects To Complete Phase 3 Dry Eye Trial In November 2020
31/08/2020 13:35
Aug 31 (Reuters) - RegeneRx Biopharmaceuticals Inc
RGRX.PK :
* REGENERX JOINT VENTURE EXPECTS TO COMPLETE PHASE 3 DRY EYE
TRIAL
IN NOVEMBER 2020
Source text for Eikon: ID:nPn7Fnlvca
Further company coverage: RGRX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RegeneRx Biopharmaceuticals
See all newsBrief: Regenerx Effects Reverse Stock Split, Terminates SEC Reporting Obligations
Brief: Regenerx Receives Stockholder Approval For Reverse Stock Split
Brief: First Patient Enrolled Into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial With Rgn-259
Brief: RegeneRx Publishes RGN-259 Phase 3 Clinical Trial Results
Brief: Regenerx Reports Topline Results Of Arise-3 Dry Eye Trial